lapatinib has been researched along with pyrimidinones in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (pyrimidinones) | Trials (pyrimidinones) | Recent Studies (post-2010) (pyrimidinones) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 6,059 | 604 | 2,692 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Liu, BR; Xie, L | 1 |
| Adair, SJ; Bauer, TW; Borgman, CA; Chopivsky, ME; Cowan, CR; Gilmer, TM; Lindberg, JM; Lowrey, BT; Newhook, TE; Parsons, JT; Stelow, EB; Stokes, JB; Walters, DM | 1 |
| Karakashev, SV; Reginato, MJ | 1 |
| Banno, E; Boku, N; De Velasco, MA; Fujita, Y; Mizukami, T; Nakajima, TE; Nishio, K; Sakai, K; Sogabe, S; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Beijnen, JH; Bernards, R; Huijberts, SCFA; Huitema, ADR; Marchetti, S; Monkhorst, K; Opdam, FL; Pulleman, S; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM | 1 |
| Kang, W; Kwon, JY; Lee, C; Lee, H; Maher, L; Michaud, M; Ning, G; Silva, M; Suh, YS; Zhang, C; Zhu, Q | 1 |
1 review(s) available for lapatinib and pyrimidinones
| Article | Year |
|---|---|
[Stem cell-targeted therapy--a new strategy for cancer treatment].
Topics: Adenosine; Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Differentiation; Diketopiperazines; Heterocyclic Compounds, 4 or More Rings; Humans; Lapatinib; Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidinones; Quinazolines; Signal Transduction; Triazines; Wnt Proteins | 2008 |
1 trial(s) available for lapatinib and pyrimidinones
| Article | Year |
|---|---|
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Lapatinib; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Treatment Outcome | 2020 |
5 other study(ies) available for lapatinib and pyrimidinones
| Article | Year |
|---|---|
Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Topics: Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 2; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Kaplan-Meier Estimate; Lapatinib; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction | 2015 |
EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2015 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Pyridones; Pyrimidines; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |